Applications of 2-Deoxy-2,2-Difluoro-D-Erythro-Pentofuranose-3,5-Dibenzoate-1-Methanesulfonate in Industrial Manufacturing

As the direct manufacturer of this specialized fluorinated carbohydrate intermediate, we supply it primarily to advanced pharmaceutical and fine chemical production sectors. This compound, with its unique protecting group profile and high fluorine content, remains integral for downstream applications where strict regulatory compliance, precise formulation, and sensitive process parameters are mandatory. Below we detail several established industrial scenarios, each reflecting the specific manufacturing context, target compliance frameworks, and application methodologies.

1. Antiviral Nucleoside Analog Synthesis

In nucleoside analog development for antiviral therapies, downstream manufacturers utilize this difluorinated pentofuranose as a pivotal protected sugar moiety. It functions as a key glycosylation donor during complex multi-step syntheses of nucleoside analogues targeting diseases such as hepatitis and influenza. The material’s orthogonal protecting groups permit selective deprotection in the presence of common functional groups and facilitate stereoselective coupling with nucleobases, supporting demanding process controls required under cGMP guidelines and major pharmacopeial standards.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP, ICH Q7)
• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur.)
• Japan Pharmacopoeia (JP)

Typical usage ratio

• 0.95–1.10 molar equivalents per nucleobase intermediate, adjusted according to coupling efficiency and scale of active pharmaceutical ingredient (API) batch; ratio often fine-tuned based on HPLC-monitored conversion during pilot-plant and commercial production.

Downstream process integration

• The material enters the glycosylation step after initial nucleobase preparation, serving as the protected sugar donor for the formation of the nucleoside core. Typical process involves Lewis acid catalysis in an anhydrous solvent system, followed by selective group removal and subsequent API elaboration.

Final product types

• Antiviral nucleoside analog APIs (e.g., sofosbuvir and guanosine analogs)
• Research-grade protected nucleoside compounds for preclinical development
• Intermediate nucleoside libraries for structure–activity relationship (SAR) studies

2. Oncology DNA Polymerase Inhibitor Development

Within the synthesis of selective DNA polymerase inhibitors used for cancer therapeutics, fine chemical manufacturers deploy this compound as an advanced glycosyl donor for layering difluorinated sugar motifs onto heterocyclic cores. These complex intermediates provide the foundation for prodrug candidates and chemically modified antimetabolites. The strict control over stereochemical outcomes, enabled by this intermediate’s benzoyl-based protection system, ensures suitability for subsequent scale-up and regulatory submission batches.

Industry compliance standards

• US Food and Drug Administration (FDA) 21 CFR Part 210/211
• ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001 quality management
• Reference to International Conference on Harmonisation (ICH) guidelines for genotoxic impurities

Typical usage ratio

• 1.0–1.2 molar equivalents per polymerase inhibitor intermediate; adjustment based on crude yield assessment and impurity profiling during process validation.

Downstream process integration

• Introduced at the glycosidation stage after derivatization of the cytosine or related nucleobase; typical reactions employ silver salt or Lewis acid catalysis, followed by chromatographic purification under validated cleaning protocols.

Final product types

• Cancer chemotherapeutic active ingredients (e.g., fluorinated cytidine analogs)
• Synthetic reference standards for oncology pipeline support
• Regulatory submission batches for clinical trial materials

3. Prodrug Intermediate Production for Hepatic Delivery

Speciality API manufacturers leverage this mesylate derivative as a central building block for producing protected sugar moieties in hepatic-targeted prodrugs, especially where fluorination influences pharmacokinetics and metabolic resistance. The molecule’s dual protection and activated leaving group configuration supports efficient downstream modifications, essential for constructing carriers that release active metabolites in a controlled manner once inside hepatic cells.

Industry compliance standards

• WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients
• Health Canada GMP Guidelines (GUI-0001)
• EMEA/CHMP/QWP/130/96 rev 1 for pharmaceutical excipients
• Site-specific quality agreements referencing QP oversight (EU)

Typical usage ratio

• Typically 1.0 molar equivalent per prodrug backbone molecule; process chemists may increase to 1.2 equivalents to maximize coupling in presence of sensitive leaving groups, monitored via UPLC assay of intermediate purity.

Downstream process integration

• Feeds into the conjugation step where it reacts with protecting group–functionalized ligands or targeting moieties; this is usually conducted in anhydrous organic solvents using phase-transfer catalysis, followed by acid-base workup and crystallization.

Final product types

• Liver-targeted prodrug intermediates
• Protected glycosyl conjugates for stability studies
• Advanced intermediates for pharmacokinetic optimization research

4. Specialty Carbohydrate Scaffold Manufacture for Medicinal Chemistry

Medicinal chemistry groups and small-molecule innovation centers routinely employ this high-purity sugar as a scaffold for constructing libraries of fluorinated carbohydrates. Its mesylate and dibenzoate functionalization supports regioselective and stereospecific derivatizations, facilitating a range of downstream chemical modifications. Careful batch release and traceability practices are required to meet the sector’s cleanroom compounding and analytical validation requirements.

Industry compliance standards

• ISO 9001:2015 quality systems for research chemical manufacturing
• GLP (Good Laboratory Practice) for medicinal chemistry
• Institute of Chemical Technology research protocols
• OECD guidelines for chemical traceability in R&D

Typical usage ratio

• 0.8–1.2 molar equivalents per scaffold core; researchers may vary this based on diversity target or solid-phase reaction efficiency, typically determined by mass balance and chromatographic analysis during parallel synthesis.

Downstream process integration

• Utilized as a primary scaffold component in solution-phase or solid-phase automated synthesis; introduced at the foundational library construction step, often under anhydrous and inert atmosphere to prevent decomposition or racemization, followed by multi-step diversifications.

Final product types

• Fluorinated carbohydrate derivative libraries for lead discovery
• Custom scaffolds for academic-industry partnership projects
• Screening panels for biotech medicinal chemistry programs